aspirin has been researched along with Insulin Sensitivity in 46 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " None of the aspirin doses had a significant impact upon BMI, blood pressure, lipid parameters, insulin sensitivity (HOMA), FRAP, TAOS, GSH, endothelial function, glycaemic control (fructosamine) or inflammation (sVCAM-1 and HsCRP)." | 9.19 | Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. ( Cummings, MH; Laight, DW; Raghavan, RP, 2014) |
| "Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases." | 8.83 | [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. ( Legrand, DA; Scheen, AJ, 2006) |
| " The aim of the present study was to examine the effect of chronic administration of aspirin on metabolic and cardiovascular parameters in fructose-fed rats (FFR), an experimental model of metabolic syndrome." | 7.75 | Effect of chronic aspirin administration on an experimental model of metabolic syndrome. ( González, ES; Lama, MC; Miatello, RM; Renna, NF; Vazquez, MA, 2009) |
| "High-dose aspirin treatment improves fasting and postprandial hyperglycaemia in patients with type 2 diabetes, as well as in animal models of insulin resistance associated with obesity and sepsis." | 7.75 | Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IRbeta/IRS-1 and Akt. ( Carvalheira, JB; Carvalho-Filho, MA; Cintra, DE; Curi, R; Pauli, RJ; Ropelle, ER; Saad, MJ; Silveira, LR; Tsukumo, DM; Velloso, LA, 2009) |
| "The aim of this study was to evaluate the relationship of obesity, leptin, insulin resistance and C-reactive protein (CRP) with coronary heart disease (CHD) risk factors in patients with Type 2 diabetes mellitus (DM) with CHD compared with those with Type 2 DM without CHD." | 7.73 | Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. ( Abdella, NA; Al Jebely, S; Al Mohammedi, H; Al Ozairi, ES; Mojiminiyi, OA; Moussa, MA; Zaki, M, 2005) |
| "To examine whether an in vivo chronic treatment with aspirin could prevent insulin resistance, oxidative stress and blood pressure elevation associated with high glucose feeding in rats." | 7.71 | Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. ( de Champlain, J; El Midaoui, A; Wu, R, 2002) |
| "Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i." | 5.42 | Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. ( Blümer, RM; Bujak, AL; Crane, JD; Day, EA; Ford, RJ; Fullerton, MD; Gerstein, HC; Kemp, BE; Marcinko, K; Oakhill, JS; Pinkosky, SL; Scott, JW; Smith, BK; Steinberg, GR, 2015) |
| "8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months." | 5.24 | Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017) |
| " None of the aspirin doses had a significant impact upon BMI, blood pressure, lipid parameters, insulin sensitivity (HOMA), FRAP, TAOS, GSH, endothelial function, glycaemic control (fructosamine) or inflammation (sVCAM-1 and HsCRP)." | 5.19 | Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. ( Cummings, MH; Laight, DW; Raghavan, RP, 2014) |
| " Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity." | 4.83 | Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006) |
| "Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases." | 4.83 | [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. ( Legrand, DA; Scheen, AJ, 2006) |
| "It was concluded that simultaneous inhibition of the JAK-STAT and NF-κB signalling pathways with tofacitinib and aspirin respectively, could mitigate insulin resistance and hyperglycemia in T2D." | 3.91 | Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. ( Bako, HY; Ibrahim, MA; Ibrahim, S; Isah, MS, 2019) |
| " The results showed that amygdalin and cinnamic acid inhibit serine phosphorylation of IRS-1 through targeting JNK serine kinase and enhance insulin sensitivity." | 3.81 | Cell lysis-free quantum dot multicolor cellular imaging-based mechanism study for TNF-α-induced insulin resistance. ( Kim, MJ; Rangasamy, S; Shim, Y; Song, JM, 2015) |
| " Two subgroups of GK and Wistar control rats were injected intraperitoneally with 100 mg aspirin/kg body weight/ day for 5 weeks." | 3.81 | Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats. ( Adeghate, E; Amiri, L; Howarth, FC; Jayaprakash, P; John, A; Raza, H; Shafarin, J; Yasin, J, 2015) |
| "Aspirin is a kind of anti-inflammatory drug and may be used to reverse hyperglycemia, hyperinsulinemia, and dyslipidemia by improving insulin resistance." | 3.77 | Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats. ( Han, F; Han, L; Sun, X; Wang, B; Yi, J, 2011) |
| " The aim of the present study was to examine the effect of chronic administration of aspirin on metabolic and cardiovascular parameters in fructose-fed rats (FFR), an experimental model of metabolic syndrome." | 3.75 | Effect of chronic aspirin administration on an experimental model of metabolic syndrome. ( González, ES; Lama, MC; Miatello, RM; Renna, NF; Vazquez, MA, 2009) |
| "High-dose aspirin treatment improves fasting and postprandial hyperglycaemia in patients with type 2 diabetes, as well as in animal models of insulin resistance associated with obesity and sepsis." | 3.75 | Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IRbeta/IRS-1 and Akt. ( Carvalheira, JB; Carvalho-Filho, MA; Cintra, DE; Curi, R; Pauli, RJ; Ropelle, ER; Saad, MJ; Silveira, LR; Tsukumo, DM; Velloso, LA, 2009) |
| " Aspirin did not alter this effect of 60 h of fasting on insulin sensitivity (P = 0." | 3.74 | Prolonged fasting induces peripheral insulin resistance, which is not ameliorated by high-dose salicylate. ( Ackermans, MT; Allick, G; Endert, E; Romijn, JA; Sauerwein, HP; van der Crabben, SN, 2008) |
| "The aim of this study was to evaluate the relationship of obesity, leptin, insulin resistance and C-reactive protein (CRP) with coronary heart disease (CHD) risk factors in patients with Type 2 diabetes mellitus (DM) with CHD compared with those with Type 2 DM without CHD." | 3.73 | Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. ( Abdella, NA; Al Jebely, S; Al Mohammedi, H; Al Ozairi, ES; Mojiminiyi, OA; Moussa, MA; Zaki, M, 2005) |
| " In this study, we demonstrate that sepsis induces insulin resistance and that pretreatment with aspirin inhibits sepsis-induced insulin resistance." | 3.72 | Aspirin inhibits serine phosphorylation of IRS-1 in muscle and adipose tissue of septic rats. ( Barreiro, GC; Caliseo, CT; Carvalheira, JB; Fugiwara, FY; Prada, PO; Prattali, RR; Saad, MJ; Ueno, M; Velloso, LA, 2004) |
| "To examine whether an in vivo chronic treatment with aspirin could prevent insulin resistance, oxidative stress and blood pressure elevation associated with high glucose feeding in rats." | 3.71 | Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. ( de Champlain, J; El Midaoui, A; Wu, R, 2002) |
| "For the patients with newly diagnosed type 2 diabetes, additional administration of CDDP to the conventional treatment could exert beneficial effects on blood glucose controling, and lipid profile improvement and delay of arterial intima-media proliferation." | 2.75 | [Effect of compound danshen dripping pill on arterial intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus]. ( Liu, D; Tang, JY; Yan, L, 2010) |
| " Therefore, several new antiplatelet treatment strategies have been developed in order to optimize platelet inhibition: a) modification of dosing of commonly used agents; b) use of new agents; and c) addition of a third antiplatelet drug (triple therapy)." | 2.48 | Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. ( Angiolillo, DJ; Ferreiro, JL, 2012) |
| "The Metabolic syndrome is a widely prevalent and multi-factorial disorder." | 2.43 | Metabolic syndrome. ( Agarwal, PK; Gogia, A, 2006) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| "Pentamidine was frequently associated with dysglycaemia due to its pancreatic beta-cell cytotoxic effects but is now used less often to treat Pneumocystis carinii pneumonia in immunosuppressed patients." | 2.39 | Drug-induced disorders of glucose metabolism. Mechanisms and management. ( Chan, JC; Cockram, CS; Critchley, JA, 1996) |
| "Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i." | 1.42 | Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. ( Blümer, RM; Bujak, AL; Crane, JD; Day, EA; Ford, RJ; Fullerton, MD; Gerstein, HC; Kemp, BE; Marcinko, K; Oakhill, JS; Pinkosky, SL; Scott, JW; Smith, BK; Steinberg, GR, 2015) |
| "Insulin resistance is a central feature of type 2 diabetes." | 1.33 | Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men. ( Bobbert, T; Freudenberg, M; Möhlig, M; Pfeiffer, AF; Ristow, M; Rochlitz, H; Spranger, J; Weickert, MO, 2006) |
| "Only clonidine treatment totally prevented the development of insulin resistance, and high-dose aspirin, known to prevent insulin resistance by inhibition of the activity of IkappaB kinase-beta, decreased the degree of insulin resistance by almost 70%." | 1.32 | Hypertension and insulin resistance are not directly related in obese dogs. ( Gokee, A; Rocchini, AP; Yang, JQ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.17) | 18.7374 |
| 1990's | 1 (2.17) | 18.2507 |
| 2000's | 24 (52.17) | 29.6817 |
| 2010's | 17 (36.96) | 24.3611 |
| 2020's | 3 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Bako, HY | 1 |
| Ibrahim, MA | 1 |
| Isah, MS | 1 |
| Ibrahim, S | 1 |
| Paven, E | 1 |
| Dillinger, JG | 1 |
| Bal Dit Sollier, C | 1 |
| Vidal-Trecan, T | 1 |
| Berge, N | 1 |
| Dautry, R | 1 |
| Gautier, JF | 1 |
| Drouet, L | 1 |
| Riveline, JP | 1 |
| Henry, P | 1 |
| Sardi, C | 1 |
| Martini, E | 1 |
| Mello, T | 1 |
| Camelliti, S | 1 |
| Sfondrini, L | 1 |
| Marcucci, F | 1 |
| Kallikourdis, M | 1 |
| Sommariva, M | 1 |
| Rumio, C | 1 |
| Guo, X | 1 |
| Li, X | 1 |
| Yang, W | 1 |
| Liao, W | 1 |
| Shen, JZ | 1 |
| Ai, W | 1 |
| Pan, Q | 1 |
| Sun, Y | 1 |
| Zhang, K | 1 |
| Zhang, R | 1 |
| Qiu, Y | 1 |
| Dai, Q | 1 |
| Zheng, H | 1 |
| Guo, S | 1 |
| Şen, S | 1 |
| Çelik, S | 1 |
| El-Kharashi, OA | 1 |
| El-Din Aly El-Waseef, DA | 1 |
| Nabih, ES | 1 |
| Mohamed, DI | 1 |
| Chakraborty, P | 1 |
| Banerjee, S | 1 |
| Saha, P | 1 |
| Nandi, SS | 1 |
| Sharma, S | 1 |
| Goswami, SK | 1 |
| Chakravarty, B | 1 |
| Kabir, SN | 1 |
| Asemi, Z | 1 |
| Samimi, M | 1 |
| Heidarzadeh, Z | 1 |
| Khorrammian, H | 1 |
| Tabassi, Z | 1 |
| Gonçalves, LH | 1 |
| Silva, MV | 1 |
| Duarte, RC | 1 |
| Dusse, LM | 1 |
| Fernandes, AP | 1 |
| Bosco, AA | 1 |
| Gomes, KB | 1 |
| Carvalho, Md | 1 |
| Raghavan, RP | 1 |
| Laight, DW | 1 |
| Cummings, MH | 1 |
| Blagosklonny, MV | 1 |
| Kim, MJ | 1 |
| Rangasamy, S | 1 |
| Shim, Y | 1 |
| Song, JM | 1 |
| Ford, RJ | 1 |
| Fullerton, MD | 1 |
| Pinkosky, SL | 1 |
| Day, EA | 1 |
| Scott, JW | 1 |
| Oakhill, JS | 1 |
| Bujak, AL | 1 |
| Smith, BK | 1 |
| Crane, JD | 1 |
| Blümer, RM | 1 |
| Marcinko, K | 1 |
| Kemp, BE | 1 |
| Gerstein, HC | 1 |
| Steinberg, GR | 1 |
| Amiri, L | 1 |
| John, A | 1 |
| Shafarin, J | 1 |
| Adeghate, E | 1 |
| Jayaprakash, P | 1 |
| Yasin, J | 1 |
| Howarth, FC | 1 |
| Raza, H | 1 |
| Lee, DH | 1 |
| Chun, EJ | 1 |
| Hur, JH | 1 |
| Min, SH | 1 |
| Lee, JE | 1 |
| Oh, TJ | 1 |
| Kim, KM | 1 |
| Jang, HC | 1 |
| Han, SJ | 1 |
| Kang, DK | 1 |
| Kim, HJ | 1 |
| Lim, S | 1 |
| Renna, NF | 1 |
| Vazquez, MA | 1 |
| Lama, MC | 1 |
| González, ES | 1 |
| Miatello, RM | 1 |
| Martha, S | 1 |
| Devarakonda, KR | 1 |
| Anreddy, RN | 1 |
| Pantam, N | 1 |
| Carvalho-Filho, MA | 1 |
| Ropelle, ER | 1 |
| Pauli, RJ | 1 |
| Cintra, DE | 1 |
| Tsukumo, DM | 1 |
| Silveira, LR | 1 |
| Curi, R | 1 |
| Carvalheira, JB | 2 |
| Velloso, LA | 2 |
| Saad, MJ | 2 |
| Yassine, HN | 1 |
| Davis-Gorman, G | 1 |
| Stump, CS | 1 |
| Thomson, SS | 1 |
| Peterson, J | 1 |
| McDonagh, PF | 1 |
| Liu, D | 1 |
| Tang, JY | 1 |
| Yan, L | 1 |
| Sun, X | 1 |
| Han, F | 1 |
| Yi, J | 1 |
| Han, L | 1 |
| Wang, B | 1 |
| Yoshikawa, Y | 1 |
| Adachi, Y | 1 |
| Yasui, H | 1 |
| Hattori, M | 1 |
| Sakurai, H | 1 |
| Ferreiro, JL | 1 |
| Angiolillo, DJ | 1 |
| Quilley, J | 1 |
| El Midaoui, A | 1 |
| Wu, R | 1 |
| de Champlain, J | 1 |
| Gao, Z | 1 |
| Zuberi, A | 1 |
| Quon, MJ | 1 |
| Dong, Z | 1 |
| Ye, J | 1 |
| Tamminen, M | 1 |
| Lassila, R | 1 |
| Westerbacka, J | 1 |
| Vehkavaara, S | 1 |
| Yki-Järvinen, H | 1 |
| Rocchini, AP | 1 |
| Yang, JQ | 1 |
| Gokee, A | 1 |
| Barreiro, GC | 1 |
| Prattali, RR | 1 |
| Caliseo, CT | 1 |
| Fugiwara, FY | 1 |
| Ueno, M | 1 |
| Prada, PO | 1 |
| Löbner, K | 1 |
| Füchtenbusch, M | 1 |
| Abdella, NA | 1 |
| Mojiminiyi, OA | 1 |
| Moussa, MA | 1 |
| Zaki, M | 1 |
| Al Mohammedi, H | 1 |
| Al Ozairi, ES | 1 |
| Al Jebely, S | 1 |
| Möhlig, M | 1 |
| Freudenberg, M | 1 |
| Bobbert, T | 1 |
| Ristow, M | 1 |
| Rochlitz, H | 1 |
| Weickert, MO | 1 |
| Pfeiffer, AF | 1 |
| Spranger, J | 1 |
| Volcy, M | 1 |
| Tepper, SJ | 1 |
| Rapoport, AM | 1 |
| Sheftell, FD | 1 |
| Bigal, ME | 1 |
| Gogia, A | 1 |
| Agarwal, PK | 1 |
| Zhang, L | 1 |
| Zheng, J | 1 |
| Li, HM | 1 |
| Meng, YX | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Karagiannis, A | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Kurukulasuriya, LR | 1 |
| Govindarajan, G | 1 |
| Sowers, J | 1 |
| Legrand, DA | 1 |
| Scheen, AJ | 1 |
| Berry, C | 1 |
| Tardif, JC | 1 |
| Bourassa, MG | 1 |
| van der Crabben, SN | 1 |
| Allick, G | 1 |
| Ackermans, MT | 1 |
| Endert, E | 1 |
| Romijn, JA | 1 |
| Sauerwein, HP | 1 |
| Masanauskiene, E | 1 |
| Naudziūnas, A | 1 |
| Newman, WP | 1 |
| Brodows, RG | 1 |
| Chan, JC | 1 |
| Cockram, CS | 1 |
| Critchley, JA | 1 |
| Steinberg, H | 1 |
| González-Ortiz, M | 1 |
| Martínez-Abundis, E | 1 |
| Balcázar-Muñoz, BR | 1 |
| Robles-Cervantes, JA | 1 |
| Yuan, M | 1 |
| Konstantopoulos, N | 1 |
| Lee, J | 1 |
| Hansen, L | 1 |
| Li, ZW | 1 |
| Karin, M | 1 |
| Shoelson, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk[NCT00898950] | 21 participants (Actual) | Interventional | 2004-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for aspirin and Insulin Sensitivity
| Article | Year |
|---|---|
Koschei the immortal and anti-aging drugs.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Caloric Restriction; Exercise; Folklore; G | 2014 |
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.
Topics: Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Ty | 2012 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arte | 2004 |
Metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exercise; Humans; Hydroxymethylglutaryl | 2006 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
Stroke prevention in diabetes and obesity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular | 2006 |
[Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Insulin Resistance; Male; | 2006 |
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Disease; Diabetes | 2007 |
[Peripheral arterial disease--an underappreciated clinical problem].
Topics: Age Factors; Aged; Ankle; Aspirin; Atherosclerosis; Brachial Artery; Diabetes Complications; Dyslipi | 2008 |
Drug-induced disorders of glucose metabolism. Mechanisms and management.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensin-Converti | 1996 |
6 trials available for aspirin and Insulin Sensitivity
| Article | Year |
|---|---|
A randomized controlled clinical trial investigating the effect of calcium supplement plus low-dose aspirin on hs-CRP, oxidative stress and insulin resistance in pregnant women at risk for pre-eclampsia.
Topics: Aspirin; Blood Glucose; C-Reactive Protein; Calcium; Dietary Supplements; Dose-Response Relationship | 2012 |
Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels.
Topics: Aspirin; Biological Transport; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agen | 2014 |
Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic | 2014 |
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph | 2017 |
[Effect of compound danshen dripping pill on arterial intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus].
Topics: Adult; Aged; Aspirin; Blood Glucose; Carotid Intima-Media Thickness; Cholesterol; Diabetes Mellitus, | 2010 |
Inhibition of cyclooxygenase-1 or -2 on insulin sensitivity in healthy subjects.
Topics: Adult; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2001 |
30 other studies available for aspirin and Insulin Sensitivity
| Article | Year |
|---|---|
Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes.
Topics: Animals; Aspirin; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2019 |
Determinants of aspirin resistance in patients with type 2 diabetes.
Topics: Aged; Arachidonic Acid; Aspirin; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus, Typ | 2020 |
Effect of acetylsalicylic acid on inflamed adipose tissue. Insulin resistance and hepatic steatosis in a mouse model of diet-induced obesity.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diet, High-Fat; Disease M | 2021 |
Metformin Targets Foxo1 to Control Glucose Homeostasis.
Topics: Animals; Aspirin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; | 2021 |
The effect of acetylsalicylic acid on vasopressin, serum insulin levels, insulin resistance, and biochemical parameters in rats induced with experimental diabetes type 2.
Topics: Animals; Aspirin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin | 2017 |
Targeting NLRP3 inflammasome via acetylsalicylic acid: Role in suppressing hepatic dysfunction and insulin resistance induced by atorvastatin in naïve versus alcoholic liver in rats.
Topics: Alcoholism; Animals; Aspirin; Atorvastatin; Bile Acids and Salts; Caspase 8; Hepatocytes; Inflammaso | 2018 |
Aspirin and low-molecular weight heparin combination therapy effectively prevents recurrent miscarriage in hyperhomocysteinemic women.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Heparin, Low- | 2013 |
Cell lysis-free quantum dot multicolor cellular imaging-based mechanism study for TNF-α-induced insulin resistance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Aspirin; Cinnamates; Forkhead Box Protein O1; F | 2015 |
Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.
Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Cardiotonic Agents; Cells, Cultured; Diabetes Melli | 2015 |
Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats.
Topics: Animals; Aspirin; Body Weight; Diabetes Mellitus, Type 2; Dinoprostone; Dose-Response Relationship, | 2015 |
Effect of chronic aspirin administration on an experimental model of metabolic syndrome.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Aspirin; Blood Glucose; Blood Pressure; Bod | 2009 |
Effect of aspirin treatment in streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Aspirin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; I-kappa B Kina | 2009 |
Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IRbeta/IRS-1 and Akt.
Topics: Animals; Aspirin; Drug Tolerance; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; | 2009 |
Clinical determinants of aspirin resistance in diabetes.
Topics: Albuminuria; Aspirin; Cohort Studies; Diabetic Angiopathies; Drug Resistance; Female; Glycated Hemog | 2010 |
Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Glucose; Diabetes Mellitus, Experim | 2011 |
Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-A(y) mice: structure-activity relationship on zinc-salicylate complexes.
Topics: Adiponectin; Administration, Oral; Animals; Aspirin; Blood Pressure; Coordination Complexes; Diabete | 2011 |
Insulin resistance, oxidative stress and aspirin: therapeutic implications?
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Glucose; Humans; Hyperglycemia; Hypertension; Insulin R | 2002 |
Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats.
Topics: Animals; Aorta; Aspirin; Blood Glucose; Blood Pressure; Body Weight; Canada; Cyclooxygenase Inhibito | 2002 |
Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases.
Topics: 3T3 Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Insulin Receptor Subst | 2003 |
Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects.
Topics: Adenosine Diphosphate; Analysis of Variance; Arachidonic Acid; Arteriosclerosis; Aspirin; Blood Gluc | 2003 |
Hypertension and insulin resistance are not directly related in obese dogs.
Topics: Adrenergic beta-Antagonists; Animals; Aspirin; Atenolol; Blood Glucose; Clonidine; Diet, Sodium-Rest | 2004 |
Aspirin inhibits serine phosphorylation of IRS-1 in muscle and adipose tissue of septic rats.
Topics: Adipose Tissue; Animals; Aspirin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mus | 2004 |
Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; C-Reactive Protein; Cardiov | 2005 |
Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men.
Topics: Adiponectin; Aspirin; Blood Glucose; C-Reactive Protein; Fatty Acids, Nonesterified; Glucose Clamp T | 2006 |
Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations.
Topics: Acetaminophen; Adult; Analgesics; Anxiety; Aspirin; Botulinum Toxins, Type A; Caffeine; Colitis, Ulc | 2006 |
Inhibitory effects of cardiotonic pills on platelet function in dogs fed a high-fat diet.
Topics: Animals; Aspirin; Blood Platelets; Calcium; Cardiotonic Agents; Dietary Fats; Disease Models, Animal | 2006 |
Prolonged fasting induces peripheral insulin resistance, which is not ameliorated by high-dose salicylate.
Topics: Adult; Aspirin; Enzyme Inhibitors; Fasting; Glucose; Glucose Clamp Technique; Glutathione; Humans; I | 2008 |
Aspirin causes tissue insensitivity to insulin in normal man.
Topics: Adult; Aspirin; Blood Glucose; Fatty Acids, Nonesterified; Glucose; Humans; Ibuprofen; Insulin; Insu | 1983 |
Meeting report of the ASPET-Ray Fuller Symposium: insulin resistance in diabetes and hypertension: syndrome X and beyond.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Endot | 2000 |
Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Glucose; Cell Line; Dietary Fats; G | 2001 |